Achillion reports positive interim results for HCV candidates
- In an open label Phase 2 proxy study, Achillion Pharmaceuticals' (NASDAQ:ACHN) NS5A inhibitor, ACH-3102, in combination with Sovaldi (sofosbuvir) achieved 100% SVR4 in 12 patients in six weeks, independent of baseline viral load, gender and IL28B status. SVR12 results will be reported in H1 2015. The combination therapy was well-tolerated with no serious adverse events reported.
- In a Phase 1 proof-of-concept study in treatment-naive HCV-1 patients, the company's nucleotide inhibitor, ACH-3422, demonstrated a mean maximum reduction in HCV viral RNA load of 4.8 log10 IU/mL within 14 days at a dose of 700 mg (once daily for 14 days). Three of six patients achieved undetectable HCV RNA (<10 iu="" li="" ml="">
- The company will conduct a conference call this morning at 8:30 am ET to discuss the results.
- Shares are up 62% premarket on robust volume.
For the latest updates on the stock market, visit,
http://daytradingstock-blog.blogspot.com
